Abstract 1815P
Background
TALAPRO-1 evaluated talazoparib in patients (pts) with mCRPC and homologous recombination repair (HRR) alterations (11-gene panel, including BRCA1/2, PALB2, and ATM), who had received at least a taxane-based chemotherapy regimen and progressed on ≥1 novel hormonal therapy. Primary endpoint was objective response rate (RECIST 1.1) by blinded independent central review. Exploratory biomarker analyses assessed ctDNA and its associations with antitumor activity.
Methods
Serial ctDNA samples from Weeks (Wks) 1, 9, and 25, and Safety follow-up visit (SFUV) were assessed using FoundationOne Liquid CDx. Plasma tumor fraction (TF) was calculated based on tumor aneuploidy as described by Husain et al ( JCO Precis Oncol 2022; 6:e2200261). Data cut-off was September 4, 2020 (primary completion date).
Results
BRCA2 mutational complexity (variants/BRCA2m pts) was 18/16 (1.1), 12/10 (1.2), 62/11 (5.6), and 57/14 (4.1) at Wks 1, 9, and 25, and SFUV, respectively. At Wk 25, the median number of BRCA2 variants was 2 (range 1–18; 3 pts had ≥15 variants). Mutational complexity increased for BRCA1 and PALB2 by Wk 25 but remained unchanged for ATM. Of 26 evaluable pts, 7 cases of emergent variants in PARP1, PARP2, or PARP3 at Wk 25 and/or SFUV were detected. These included 5 cases of PARP1 variants predicted to truncate PARP1 and/or inhibit talazoparib binding, including 3 cases of A898T. 15/27 pts had TF quantifiable at Wk 1 (range 10−68%). Of these 15 pts, 10 had TF below limit of quantitation (BLQ; 10%), 1 had TF reduction ≥50%, and 4 had TF unchanged (change <50%) at Wk 9. Reductions to BLQ were seen in 4/4 with partial response, 2/2 with non-complete response/non-progressive disease, 3/5 with stable disease (an additional patient reduced ≥50%), and 1/4 with progressive disease.
Conclusions
Increased mutational complexity of genes in the BRCA1-PALB2-BRCA2 axis and emergent PARP variants likely reflects selective pressure to escape talazoparib-mediated synthetic lethality and/or PARP trapping. Early reductions in TF were evident and numerically more common in pts with antitumor responses. Further exploration of emergent variants in HRR and PARP genes and of ctDNA burden are warranted.
Clinical trial identification
NCT03148795.
Editorial acknowledgement
Editorial support was provided by Ama Edusei, PharmD, of CMC Affinity, a division of IPG Health Medical Communications.
Legal entity responsible for the study
Pfizer is responsible for the governance, coordination and running of the study.
Funding
Pfizer.
Disclosure
E. Castro: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Janssen, MSD, Bayer, Pfizer; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Clovis, Pfizer; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Institutional, Funding: AstraZeneca, Pfizer; Financial Interests, Institutional, Research Grant: Janssen, Bayer; Financial Interests, Institutional, Local PI: Janssen, Pfizer. D. Laird: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks or ownership: Pfizer. T. Dorff: Financial Interests, Institutional, Advisory Board: Exelixis; Financial Interests, Personal, Other, drafted educational content (unbranded): Astellas; Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Sanofi. S. Zhao: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, EMD Serono, Exelixis, Janssen, Pfizer, Sanofi, and Seattle Genetics; Financial Interests, Personal, Research Funding: Pfizer. I.M. van Oort: Financial Interests, Personal, Speaker, Consultant, Advisor: AAA Novartis, Astellas Pharma, Bayer, Janssen, and MSD/AstraZeneca; Financial Interests, Personal, Research Funding: Astellas Pharma and Bayer. D. Gasparro: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Janssen, Pfizer, and Sanofi. F. Calabro': Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, BMS, Ipsen, Merck, MSD, and Pfizer; Financial Interests, Institutional, Research Funding: AstraZeneca, Bayer, BMS, Eisai, Icon, Iqvia, J&J, Janssen, MSD, Parexel, Pfizer, PRA, Roche, and Syneos. S. Pignata: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, clovis, GSK, PharmaMar; Financial Interests, Institutional, Funding: Roche, MSD, Pfizer, AstraZeneca. L. Geczi: Financial Interests, Personal, Invited Speaker, Honoraria: BMS, Merck, and Pfizer. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, GILEAD; Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen. D. Kilari: Financial Interests, Personal, Invited Speaker: Astellas, Janssen, Pfizer, Aveo oncology; Financial Interests, Personal, Advisory Board: Exelixis; Financial Interests, Institutional, Coordinating PI: Exelixis, Genentech; Financial Interests, Institutional, Local PI: Jounce. J.F. Hopkins: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine; Financial Interests, Personal, Stocks or ownership: Roche Holding AG. H. Chen, C.G. Healy, J. Chelliserry: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks or ownership: Pfizer. G. Scagliotti: Financial Interests, Personal, Royalties: AstraZeneca, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, and Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, BeiGene, and Eli Lilly; Financial Interests, Institutional, Research Grant: Eli Lilly, MSD, and Tesaro; Financial Interests, Personal, Other, Travel & Accommodation: Bayer. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo; Financial Interests, Institutional, Advisory Board: Harpoon; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS, Janssen, BMS; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Leadership Role, Head of the Prostate Cancer Working group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Principal Investigator, co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Leadership Role: Castration-resistant Prostate Cancer Registry. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Personal, Advisory Board, February 2022: Arvinas; Financial Interests, Personal, Advisory Board, April 2022: Macrogenics; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14